Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, OpenLabel, Phase 1b Trial

被引：2

作者：

Strati, Paolo ^{[1
]}

Christian, Beth ^{[2
]}

Martin, Peter ^{[3
]}

Champion, Becky ^{[4
]}

Coleman, Morton ^{[5
]}

Agajanian, Richy ^{[6
]}

Smith, Sonali M. ^{[7
]}

Venugopal, Parameswaran ^{[8
]}

Lossos, Izidore S. ^{[9
]}

Kridel, Robert ^{[10
]}

Calvo, Roser ^{[11
]}

Higgins, Kara ^{[12
]}

Stephens, Deborah M. ^{[13
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA

[3] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[4] Norton Canc Inst, Louisville, KY USA

[5] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[6] Oncol Inst Hope & Innovat, Downey, CA USA

[7] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[8] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[9] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[10] Princess Margaret Canc Ctr, Toronto, ON, Canada

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, San Francisco, CA USA

[13] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

关键词：

D O I：

10.1182/blood-2022-159158

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3606 / 3608

页数：3